TY - JOUR
T1 - Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma
T2 - initial experience from India
AU - Rishi, Pukhraj
AU - Manchegowda, Pradeep T.
AU - Gondhale, Harshal P.
AU - Rishi, Ekta
AU - Das, Kalpita
AU - Krishnakumar, Subramanian
AU - Raja, Thirumalairaj
AU - Biswas, Jyotirmay
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature B.V.
PY - 2021/7
Y1 - 2021/7
N2 - Purpose: To evaluate treatment outcomes and complications of intravitreal rituximab (IVR) monotherapy for eyes with vitreoretinal lymphoma (VRL). Methods: Patients diagnosed with ‘isolated primary VRL’ or ‘VRL with remission of systemic disease’ and treated with IVR (1 mg/0.1 ml) between June 2014 and June 2019 were included in this retrospective, interventional case series. Injections were repeated at monthly intervals until complete resolution. All patients signed a written informed consent form. Institutional review board approval was obtained. Results: Twelve eyes of 7 patients with VRL were treated with 77 IVR injections at mean 6.42 injections per eye (median = 5; range = 2–13) for complete resolution at mean 8.16 ± 4.62 months (median = 6.97 months; range = 1.97–14.33 months). Mean age at presentation was 53.3 years (median = 54 years; range = 34–74 years). Patients were co-managed with medical oncologist and periodically evaluated. Complications included anterior uveitis (n = 6), raised intraocular pressure (n = 3), posterior synechiae (n = 2), vitreous haemorrhage (n = 1), pre-retinal haemorrhage (n = 1), retinal detachment (n = 1), posterior subcapsular cataract (n = 2) and sectoral iris atrophy (n = 1). Recurrences were seen in 3 eyes (25%), which eventually achieved complete resolution with treatment. None of the patients had systemic involvement or death during follow-up. Mean follow-up was 18.73 ± 8.83 months (median = 21.60 months; range = 7.37–32.67 months). Conclusion: Intravitreal rituximab monotherapy is effective in management of vitreoretinal lymphoma in patients with isolated ocular disease.
AB - Purpose: To evaluate treatment outcomes and complications of intravitreal rituximab (IVR) monotherapy for eyes with vitreoretinal lymphoma (VRL). Methods: Patients diagnosed with ‘isolated primary VRL’ or ‘VRL with remission of systemic disease’ and treated with IVR (1 mg/0.1 ml) between June 2014 and June 2019 were included in this retrospective, interventional case series. Injections were repeated at monthly intervals until complete resolution. All patients signed a written informed consent form. Institutional review board approval was obtained. Results: Twelve eyes of 7 patients with VRL were treated with 77 IVR injections at mean 6.42 injections per eye (median = 5; range = 2–13) for complete resolution at mean 8.16 ± 4.62 months (median = 6.97 months; range = 1.97–14.33 months). Mean age at presentation was 53.3 years (median = 54 years; range = 34–74 years). Patients were co-managed with medical oncologist and periodically evaluated. Complications included anterior uveitis (n = 6), raised intraocular pressure (n = 3), posterior synechiae (n = 2), vitreous haemorrhage (n = 1), pre-retinal haemorrhage (n = 1), retinal detachment (n = 1), posterior subcapsular cataract (n = 2) and sectoral iris atrophy (n = 1). Recurrences were seen in 3 eyes (25%), which eventually achieved complete resolution with treatment. None of the patients had systemic involvement or death during follow-up. Mean follow-up was 18.73 ± 8.83 months (median = 21.60 months; range = 7.37–32.67 months). Conclusion: Intravitreal rituximab monotherapy is effective in management of vitreoretinal lymphoma in patients with isolated ocular disease.
KW - Eye
KW - Intravitreal injection
KW - Lymphoma
KW - Retina
KW - Rituximab
KW - Vitreous
UR - http://www.scopus.com/inward/record.url?scp=85102581014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102581014&partnerID=8YFLogxK
U2 - 10.1007/s10792-021-01805-1
DO - 10.1007/s10792-021-01805-1
M3 - Article
C2 - 33730314
AN - SCOPUS:85102581014
SN - 0165-5701
VL - 41
SP - 2495
EP - 2504
JO - International Ophthalmology
JF - International Ophthalmology
IS - 7
ER -